Sugi Predict

Sugi Predict / Compounds / SCHEMBL5875943

SCHEMBL5875943

SCHEMBL5875943

Cc1ccc(S(=O)(=O)n2nc(N)c3c2CC(c2ccccc2)(c2ccncc2)C=C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 5/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ CYP2C19 P33261 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ CXCL8 P10145 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ NOD1 Q9Y239 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ SLC9A1 P19634 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ GBA1 P04062 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ RIPK3 Q9Y572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877093 0.96 KMT2A (0.40) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5875992 0.95 ALDH1A1 (0.41) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876013 0.92 ALDH1A1 (0.36) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5877161 0.90 MAPT (0.40) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876256 0.89 ALDH1A1 (0.35) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5877595 0.88 ALDH1A1 (0.38) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876602 0.88 MAPT (0.41) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876976 0.88 ALDH1A1 (0.36) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876867 0.88 MAPT (0.47) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL5876036 0.88 KMT2A (0.42) ALDH1A1MAPTLMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 — — US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 — — US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 — — EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT ALDH1A1 166/4885MAPT 1879/4885LMNA 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.